Pathway Pathology: Histological Differences Between ErbB/Ras and Wnt Pathway Transgenic Mammary Tumors
- 30 September 2002
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 161 (3), 1087-1097
- https://doi.org/10.1016/s0002-9440(10)64269-1
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- β-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary glandOncogene, 2001
- Protein kinase CK2 in mammary gland tumorigenesisOncogene, 2001
- Endogenous Protein Kinase CK2 Participates in Wnt Signaling in Mammary Epithelial CellsPublished by Elsevier BV ,2000
- Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female miceOncogene, 1997
- Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic miceOncogene, 1997
- The myoepithelial defense: a host defense against cancerMedical Hypotheses, 1997
- N-Ethyl-N-nitrosourea induces mammary cancers in the pituitary-isografted mouse which are histologically and genotypically distinct from those induced by N-methyl-N-nitrosoureaCancer Letters, 1996
- Activated neu Induces Rapid Tumor ProgressionJournal of Biological Chemistry, 1996
- MMTV-induced mutations in mouse mammary tumors: Their potential relevance to human breast cancerBreast Cancer Research and Treatment, 1996
- Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?European Journal of Cancer, 1992